Clovis Oncology, Inc. (CLVS) Social Stream



Clovis Oncology, Inc. (CLVS): $0.08

0.00 (-5.58%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add CLVS to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#108 of 385

in industry

CLOVIS ONCOLOGY INC (CLVS) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering CLVS.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-04 4 $8 $4.75 $6.25 $0.08 7712.5%
2022-02-23 3 $8 $3 $5.5 $0.08 6775%
2022-05-06 3 $4 $3 $3.5 $0.08 4275%
2022-07-13 3 $3 $3 $3 $0.08 3650%
2022-10-21 2 $2 $2 $2 $0.08 2400%

The Trend in the Analyst Price Target


Over the past 22 months, CLVS's average price target has gone down $5.33.

Over the past 38 weeks, CLVS's average upside potential has been 122.23%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-01-26 3 8 3 5.5 1.920 186.46%
2022-05-06 3 3 3 3.0 0.991 202.72%
2022-07-13 3 3 3 3.0 2.460 21.95%
2022-10-21 2 2 2 2.0 1.080 85.19%
2022-10-21 1 2 2 2.0 1.080 85.19%

CLVS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
4 0 0 1 1 1 2

The Trend in the Broker Recommendations


Over the past 52 weeks, CLVS's average broker recommendation rating improved by 0.33.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CLVS as an investment opportunity.

  • To contextualize these metrics, consider that out of all US stocks, CLOVIS ONCOLOGY INC's upside potential (average analyst target price relative to current price) is greater than 893.03% of them.
  • In terms of how CLOVIS ONCOLOGY INC fares relative to all US stocks, note that its average analyst price target is greater than 23.53% of that group.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, CLOVIS ONCOLOGY INC's number of analysts covering the stock is higher than 59.33% of them.
  • CLOVIS ONCOLOGY INC's variance in analysts' estimates is lower than -74.38% of Pharmaceutical Products stocks.

Stocks similar to CLOVIS ONCOLOGY INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are IRWD, AGIO, and ESPR.

Is CLVS a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!